Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), has reported its financial and operational results for the second quarter of 2026, ended June 30, 2026.
As of June 30, 2026, the Company’s combined cash and cash equivalents, and digital assets, totaled approximately US$9.5 million, an increase from US$4.1 million as of December 31, 2025. Assuming the current cash burn rate for the first half of 2026, management confirms that current liquidity is sufficient to fund planned operations to at least October 2027.
Subsequent to quarter-end, the Company received U.S. Food and Drug Administration (FDA) approval to proceed with its Lucid-MS Phase 2 clinical trial in progressive multiple sclerosis, a pivotal regulatory milestone that advances the Company’s patented, first-in-class neuroprotective program into the next stage of clinical development.
A welcome email is on its way. If you don't see it, please check your junk folder.
Quantum delivered another quarter of disciplined execution, materially reducing both operating expenses and cash burn year-over-year while strengthening its treasury and overall balance sheet.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.
